Skip to main content

Advertisement

SpringerLink
Log in

The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Studies consistently showed that sodium-glucose cotransporter inhibitors (SGLTi) have cardiovascular and renal benefits, independent of their glucose lowering effects. Recent studies showed that SGLTi might influence gut microbiota. We performed a narrative review of publications focusing on use of SGLTi and changes in gut microbiota. Most studies showed that use of SGLTi re-shapes gut microbiota. These studies are heterogeneous regarding in study designs, doses and types of drugs used (SGLT1i vs. SGLT2i, or SGLT1/2i in combination) and the methods used to determine gut microbiota. However, existing data showed that SGLTi might alter food fermentation and gut permeability, which might translate into clinical outcomes. Thus the objective of this review is to summarize and discuss the updated data regarding SGLTi and changes in gut microbiota for the first time and suggest further study points that needs to be discovered.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Salah HM, Al’Aref SJ, Khan MS, et al. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J. 2021;233:86–91.

    Article  CAS  PubMed  Google Scholar 

  2. Afsar B, Afsar RE. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms. Pharmacol Rep. 2023;75(1):44–68.

    Article  CAS  PubMed  Google Scholar 

  3. Lee DM, Battson ML, Jarrell DK, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17(1):62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017;32(4):300–13.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–20.

    Article  PubMed  Google Scholar 

  6. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014;7(1):17–44.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510–9.

    Article  CAS  PubMed  Google Scholar 

  9. Montandon SA, Jornayvaz FR. Effects of antidiabetic drugs on gut microbiota composition. Genes (Basel). 2017;8(10):250.

  10. Evenepoel P, Meijers B, Masereeuw R, Lowenstein J. Effects of an SGLT inhibitor on the production, toxicity, and elimination of gut-derived uremic toxins: a call for additional evidence. Toxins (Basel). 2022;14(3):210.

  11. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Du F, Hinke SA, Cavanaugh C, et al. Potent sodium/glucose cotransporter SGLT1/2 Dual inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in rodents. J Pharmacol Exp Ther. 2018;365(3):676–87.

    Article  CAS  PubMed  Google Scholar 

  13. Sayour AA, Oláh A, Ruppert M, Barta BA, Merkely B, Radovits T. Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis. Sci Rep. 2024;14(1):2188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ho HJ, Kikuchi K, Oikawa D, et al. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure. Physiol Rep. 2021;9(24):e15092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014;4(6):e121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms. 2020;8(11):1715.

  18. Oh TJ, Sul WJ, Oh HN, et al. Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment. Sci Rep. 2019;9(1):20300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mishima E, Fukuda S, Kanemitsu Y, et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am J Physiol Renal Physiol. 2018;315(4):F824-f833.

    Article  CAS  PubMed  Google Scholar 

  20. Yang M, Shi FH, Liu W, et al. Dapagliflozin modulates the fecal microbiota in a type 2 diabetic rat model. Front Endocrinol (Lausanne). 2020;11:635.

    Article  PubMed  Google Scholar 

  21. Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH. Biomedicines. 2021;9(4):353.

  22. Kleerebezem M, Vaughan EE. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Microbiol. 2009;63:269–90.

    Article  CAS  PubMed  Google Scholar 

  23. Li Z, Wang K, Ding Y, et al. Dapagliflozin modulates the faecal microbiota after myocardial infarction in non-diabetic mice. Clin Exp Pharmacol Physiol. 2023;50(1):68–81.

    Article  CAS  PubMed  Google Scholar 

  24. Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol. 2019;11:133–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Mori K, Saito R, Nakamaru Y, Shimizu M, Yamazaki H. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Biopharm Drug Dispos. 2016;37(8):491–506.

    Article  CAS  PubMed  Google Scholar 

  26. Franklin CL, Ericsson AC. Microbiota and reproducibility of rodent models. Lab Anim (NY). 2017;46(4):114–22.

    Article  PubMed  Google Scholar 

  27. van Bommel EJM, Herrema H, Davids M, Kramer MHH, Nieuwdorp M, van Raalte DH. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. Diabetes Metab. 2020;46(2):164–8.

    Article  PubMed  Google Scholar 

  28. Bauer PV, Duca FA, Waise TMZ, et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab. 2018;27(1):101-117.e105.

    Article  CAS  PubMed  Google Scholar 

  29. Deng X, Zhang C, Wang P, et al. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab. 2022;107(7):1888–96.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45.

    Article  CAS  PubMed  Google Scholar 

  31. Furuse SU, Ohse T, Jo-Watanabe A, Shigehisa A, Kawakami K, Matsuki T, Chonan O, Nangaku M. Galacto-oligosaccharides attenuate renal injury with microbiota modification. Physiol Rep. 2014;2(7):e12029.

  32. Li YJ, Chen X, Kwan TK, et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of g protein-coupled receptors GPR43 and GPR109A. J Am Soc Nephrol. 2020;31(6):1267–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.

    CAS  PubMed  Google Scholar 

  34. Okamura T, Hamaguchi M, Mori J, Yamaguchi M, Mizushima K, Abe A, Ozeki M, Sasano R, Naito Y, Fukui M. Partially hydrolyzed guar gum suppresses the development of sarcopenic obesity. Nutrients. 2022;14(6):1157.

  35. Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(12):159234.

    Article  CAS  PubMed  Google Scholar 

  36. Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, Kitagawa N, Hashimoto Y, Majima S, Senmaru T, Okada H, Ushigome E, Nakanishi N, Takakuwa H, Sasano R, Hamaguchi M, Fukui M. Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice. Nutrients. 2022;14(17):3531.

  37. Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020;319(6):H1227-h1233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38(2):99–103.

    Article  CAS  PubMed  Google Scholar 

  39. Barbara G, Barbaro MR, Fuschi D, et al. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr. 2021;8:718356.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938–47.

    Article  CAS  PubMed  Google Scholar 

  41. Norris GH, Blesso CN. Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease. Nutr Rev. 2017;75(4):274–85.

    Article  PubMed  Google Scholar 

  42. Sun L, Pang Y, Wang X, et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 2019;9(4):702–10.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.

    Article  PubMed  Google Scholar 

  44. Wang X, Wang Z, Liu D, et al. Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and gut microbiota dysbiosis in mice with diabetic cardiovascular disease. Front Pharmacol. 2022;13:839640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Khalaf EM, Hassan HM, El-Baz AM, et al. A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation. Eur J Pharmacol. 2022;931:175172.

    Article  CAS  PubMed  Google Scholar 

  46. Shi J, Qiu H, Xu Q, et al. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice. iScience. 2023;26(1):105816.

    Article  CAS  PubMed  Google Scholar 

  47. Wang L, Liang C, Song X, et al. Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1256292.

    Article  PubMed  Google Scholar 

  48. Bao N, Liu X, Zhong X, et al. Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure. PeerJ. 2023;11:e15589.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hao H, Li Z, Qiao SY, et al. Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora. Atherosclerosis. 2023;371:32–40.

    Article  CAS  PubMed  Google Scholar 

  50. Wu J, Chen Y, Yang H, et al. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice. Front Endocrinol (Lausanne). 2023;14:1026040.

    Article  PubMed  Google Scholar 

  51. Matsui A, Yoshifuji A, Irie J, et al. Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats. Clin Exp Nephrol. 2023;27(4):295–308.

    Article  CAS  PubMed  Google Scholar 

  52. Huang C, Qian J, Liu Y, Zhang L, Yang Y. Empagliflozin attenuates liver fibrosis in high-fat diet/streptozotocin-induced mice by modulating gut microbiota. Clin Exp Pharmacol Physiol. 2024;51(3):e13842.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None declared.

Author information

Authors and Affiliations

  1. Suleyman Demirel University, School of Medicine, Department of Nephrology, Isparta, Turkey

    Baris Afsar & Rengin Elsurer Afsar

  2. Saint Louis University, School of Medicine, Division of Nephrology, St. Louis, MO, USA

    Rengin Elsurer Afsar & Krista L. Lentine

Authors
  1. Baris Afsar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rengin Elsurer Afsar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krista L. Lentine
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Baris Afsar: Conceptualization, database search. tables and writing (original draft), Rengin Elsurer Afsar: Graphs and writing (manuscript revision). All authors approved the final version of the article. Krista L Lentine: Supervision, writing and reviewing manuscript.

Corresponding author

Correspondence to Baris Afsar.

Ethics declarations

Conflict of interest

None declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afsar, B., Afsar, R.E. & Lentine, K.L. The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review. J Diabetes Metab Disord (2024). https://doi.org/10.1007/s40200-024-01435-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40200-024-01435-1

Keywords

Search

Navigation